<DOC>
	<DOCNO>NCT00385515</DOCNO>
	<brief_summary>Oral mucositis ( OM ) common debilitate toxicity induce many chemotherapy ( CT ) regimens radiation head neck . The purpose study determine effectiveness SNX-1012 decreasing duration Grade 2 , 3 , 4 oral mucositis ( OM ) accord World Health Organization ( WHO ) criterion .</brief_summary>
	<brief_title>Efficacy SNX-1012 Treatment Oral Mucositis</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Meclocycline</mesh_term>
	<mesh_term>Oxytetracycline</mesh_term>
	<criteria>Signed write informed consent Naive focal radiation therapy head neck region cancer prior CT Cycle 1 . Subjects prior concomitant radiation therapy area head neck may enrol . Histologically confirm diagnosis breast lung cancer ( NSCLC SCLC ) Chemotherapy regimen contain AC ± T EC ± T ( breast cancer ) , cisplatin carboplatin ( NSCLC SCLC ) , doxorubicin ( SCLC ) Subjects receive regimen dose CT OM Treatment CT Cycle administer immediately precede CT Cycle . Subjects OM WHO Grade great equal 2 CT Cycle 1 Cycle 2 Subjects 18 year old Karnofsky Performance Score &gt; =60 Baseline laboratory assessment : Hemoglobin ( Hgb ) level &gt; = 9 g/dL Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10 9/L Platelet count &gt; = 100 x 10 9/L Serum bilirubin level &lt; = 1.5 time institutional upper limit normal ( ULN ) Serum aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) level &lt; = 2 time ULN Females childbearing potential must negative serum urine pregnancy test result screen visit prior start Cycle 1 visit schedule &lt; = 48 hour prior start OM Treatment CT Cycle Subjects reproductive capability must agree practice adequate contraception method ( male must use condom surgically sterilize ; female must surgically sterilize , postmenopausal least 1 year , use appropriate double barrier method , prescribed birth control oral contraceptive , patch , implant , injection course study 30 day completion study assessment ) Absence serious concurrent medical illness Psychologically able participate comply study requirement Prior history oral mucositis previous chemotherapy treatment Previous treatment anthracycline agent ( lowdose neoadjuvant therapy ) Active liver disease serum AST and/or ALT level &gt; 2 time ULN Currently receive investigational agent , plan receive investigational agent study period , receive investigational agent within 30 day first dose SNX1012 Use immunosuppressive regimen systemic corticosteroid Unwilling/unable receive periodic oral assessment study evaluator unable complete daily selfreported outcome questionnaire Pregnant breastfeed woman Bronchoalveolar carcinoma Metastases central nervous system Prior plan focal radiation therapy head neck region treatment cancer ( prior radiation area head neck permit ) Presence active history chronic oral mucosal disease Presence history primary malignancy ( curatively treat nonmelanoma skin cancer allow ) History chronic liver disease Active hepatitis A B Unable receive CT OM Treatment CT Cycle regimen and/or dose immediately precede CT cycle . Known sensitivity tetracycline Known seropositive HIV HCV Use immunosuppressive regimen systemic corticosteroid . Current alcohol dependence drug abuse Psychological , social familial geographical reason would hinder prevent study visit Compromised ability give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>